Document Detail

Speculations on difference between tricyclic and selective serotonin reuptake inhibitor antidepressants on their cardiac effects. Is there any?
MedLine Citation:
PMID:  10213794     Owner:  NLM     Status:  MEDLINE    
The cardiovascular effects and toxicity of tricyclic antidepressants (TCAs) have been well documented in medical literature. The most common manifestation of such effects is slowing of intraventricular conduction, manifested by prolonged PR, QRS and QT intervals on the standard electrocardiogram (ECG) and postural hypotension. In contrast to TCAs, selective serotonin reuptake inhibitors (SSRIs), including fluoxetine and citalopram, are considered to cause less effect on cardiac impulse conduction. In addition, these compounds induced significantly less anticholinergic, antihistaminergic and cardiotoxic side-effects than TCAs. However, there is an increasing number of case reports on dysrhythmias, like atrial fibrillation or bradycardia and syncope associated with fluoxetine and another SSRI treatment and overdose. Although such reports have not been common, they do raise concerns. In cardiac tissues isolated from canine, rabbit, rat and guinea pig hearts we have found that fluoxetine and citalopram inhibited cardiac Na+ and Ca2+ channels. These direct cardiac electrophysiological effects were similar to those of observed for tricyclic antidepressants clomipramine and imipramine. The inhibition of cardiac Ca2+ and Na+ channels by fluoxetine may explain most cardiac side-effects observed occasionally with the drug and mild but significant bradycardia reported during chronic treatment. Our results suggest that fluoxetine and citalopram may have antiarrhythmic (class I + IV type), as well as proarrhythmic properties (due to impairment of atrioventricular or intraventricular conduction and shortening of repolarization). Taking all these into consideration, in depressed patients having also severe cardiac disorders, ECG control may be suggested during fluoxetine and probable another SSRI therapy. The primary goal of this review is to compare these direct cardiac effects of fluoxetine and citalopram to those of previously reported for TCAs. This paper also summarizes the recently observed effects of fluoxetine apparently not related to the blockage of 5-HT transporter based on literature.
P Pacher; Z Ungvari; P P Nanasi; S Furst; V Kecskemeti
Related Documents :
10688324 - Changes in autonomic activity and ventricular repolarization.
2416504 - Drug-induced torsade de pointes.
1778194 - The electrophysiological effects of flosequinan.
11565214 - Torsade de pointes induced by ajmaline.
7423034 - Effect of extent of myocardial damage on the behavior of myocardial zinc in albino rats.
15958354 - Trends in reperfusion therapy of st segment elevation myocardial infarction in switzerl...
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Current medicinal chemistry     Volume:  6     ISSN:  0929-8673     ISO Abbreviation:  Curr. Med. Chem.     Publication Date:  1999 Jun 
Date Detail:
Created Date:  1999-07-15     Completed Date:  1999-07-15     Revised Date:  2007-02-12    
Medline Journal Info:
Nlm Unique ID:  9440157     Medline TA:  Curr Med Chem     Country:  NETHERLANDS    
Other Details:
Languages:  eng     Pagination:  469-80     Citation Subset:  IM    
Department of Pharmacology, Semmelweis University of Medicine, P.O. Box 370, Budapest, H-l445, Hungary. PACHPAL@NET.SOTE.HU
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antidepressive Agents, Second-Generation / adverse effects,  pharmacology*
Calcium Channel Blockers / adverse effects,  pharmacology
Citalopram / adverse effects,  pharmacology
Fluoxetine / adverse effects,  pharmacology
Guinea Pigs
Heart / drug effects*,  physiology
Serotonin Uptake Inhibitors / adverse effects,  pharmacology*
Sodium Channel Blockers
Reg. No./Substance:
0/Antidepressive Agents, Second-Generation; 0/Calcium Channel Blockers; 0/Serotonin Uptake Inhibitors; 0/Sodium Channel Blockers; 54910-89-3/Fluoxetine; 59729-33-8/Citalopram

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The mammalian aquaporin water channel family: A promising new drug target.
Next Document:  Transmembrane pH gradients in vivo: measurements using fluorinated vitamin B6 derivatives.